−Removed: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
−Removed: are not currently exposed to significant market risk related to changes in interest rates.
−Removed: As of June 30, 2021, our cash equivalents
−Removed: consisted primarily of short-term money market funds.
−Removed: Our primary exposure to market risk is interest rate sensitivity, which is affected
−Removed: by changes in the general level of U.S.
+Added: QUANTITATIVE AND QUALITATIVE DISCLOSURES
+Added: ABOUT MARKET RISK.
+Added: We are not currently exposed
+Added: to significant market risk related to changes in interest rates.
+Added: As of September 30, 2021, our cash equivalents consisted primarily of
+Added: short-term money market funds.
+Added: Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general
+Added: level of U.S.
interest rates.
−Removed: Due to the short-term nature of the cash equivalents in our portfolio and the
−Removed: low risk profile of our cash equivalents, an immediate 10% change in interest rates would not have a material effect on the fair market
−Removed: value of our financial position or results of operations.
−Removed: are not currently exposed to significant market risk related to changes in foreign currency exchange rates.
−Removed: Our operations may be subject
−Removed: to fluctuations in foreign currency exchange rates in the future.
−Removed: generally affects us by increasing our cost of labor and clinical trial costs.
−Removed: We do not believe that inflation had a material effect
−Removed: on our business, financial condition or results of operations during the six months ended June 30, 2021 and 2020.
+Added: Due to the short-term nature of the cash equivalents in our portfolio and the low risk profile of our cash
+Added: equivalents, an immediate 10% change in interest rates would not have a material effect on the fair market value of our financial position
+Added: or results of operations.
+Added: We are not currently exposed
+Added: to significant market risk related to changes in foreign currency exchange rates.
+Added: Our operations may be subject to fluctuations in foreign
+Added: currency exchange rates in the future.
+Added: Inflation generally affects
+Added: us by increasing our cost of labor and clinical trial costs.
+Added: We do not believe that inflation had a material effect on our business, financial
+Added: condition, or results of operations during the nine months ended September 30, 2021 and 2020.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.